5-[2-[(3R)-1-(3-methoxypropanoyl)piperidin-3-yl]-6-methyl-4-pyridinyl]-N-methylpyridine-2-carboxamide
C22H28N4O3 — CID 95813915
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[2-[(3R)-1-(3-methoxypropanoyl)piperidin-3-yl]-6-methyl-4-pyridinyl]-N-methylpyridine-2-carboxamide
5-[2-[(3R)-1-(3-methoxypropanoyl)piperidin-3-yl]-6-methyl-4-pyridinyl]-N-methylpyridine-2-carboxamide (PubChem CID 95813915) has the molecular formula C22H28N4O3 and a molecular weight of 396.49 g/mol. Its IUPAC name is 5-[2-[(3R)-1-(3-methoxypropanoyl)piperidin-3-yl]-6-methyl-4-pyridinyl]-N-methylpyridine-2-carboxamide.
Molecular Properties
| Compound Name | 5-[2-[(3R)-1-(3-methoxypropanoyl)piperidin-3-yl]-6-methyl-4-pyridinyl]-N-methylpyridine-2-carboxamide |
|---|---|
| PubChem CID | 95813915 |
| Molecular Formula | C22H28N4O3 |
| Molecular Weight | 396.49 g/mol |
| Exact Mass | 396.22 |
| IUPAC Name | 5-[2-[(3R)-1-(3-methoxypropanoyl)piperidin-3-yl]-6-methyl-4-pyridinyl]-N-methylpyridine-2-carboxamide |
| SMILES | CNC(=O)c1ccc(-c2cc(C)nc([C@@H]3CCCN(C(=O)CCOC)C3)c2)cn1 |
| InChI | InChI=1S/C22H28N4O3/c1-15-11-18(16-6-7-19(24-13-16)22(28)23-2)12-20(25-15)17-5-4-9-26(14-17)21(27)8-10-29-3/h6-7,11-13,17H,4-5,8-10,14H2,1-3H3,(H,23,28)/t17-/m1/s1 |
| InChIKey | DZDIEARCYXEQNT-QGZVFWFLSA-N |
| XLogP | 2.55 |
| TPSA | 84.42 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 396.49 |
| LogP ≤ 5 | 2.55 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 95813915 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.